C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo M Hirvonen, A Laakso, K Na˚gren, JO Rinne, T Pohjalainen, J Hietala Dopamine D2 receptor (DRD2) is involved in the biology of several neuropsychiatric disorders and is an important target of antipsychotic drug treatment. There is a high inter-individual variation in striatal DRD2 density in vivo, part of which is explained by genetic factors. The positron emission tomography study showed that C957T polymorphism of the human DRD2 gene affected markedly striatal DRD2-binding potential in man. This indicates that the C957T polymorphism is an important DRD2 regulating factor in vivo and an interesting candidate for genetic predisposition studies in neuropsychiatric disorders.
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C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo M Hirvonen, A Laakso, K Na˚gren, JO Rinne, T Pohjalainen, J Hietala Dopamine D2 receptor (DRD2) is involved in the biology of several neuropsychiatric disorders and is an important target of antipsychotic drug treatment. There is a high inter-individual variation in striatal DRD2 density in vivo, part of which is explained by genetic factors. The positron emission tomography study showed that C957T polymorphism of the human DRD2 gene affected markedly striatal DRD2-binding potential in man. This indicates that the C957T polymorphism is an important DRD2 regulating factor in vivo and an interesting candidate for genetic predisposition studies in neuropsychiatric disorders.
Neuregulin 1: genetic support for schizophrenia subtypes SC Bakker, MLC Hoogendoorn, J-P Selten, W Verduijn, PL Pearson, RJ Sinke, RS Kahn It has been suggested that different (genetic) factors contribute to the development of schizophrenia. The NRG1 gene has repeatedly been shown to be associated with schizophrenia. The authors investigated three DNA variants around this gene in 130 Dutch patients with chronic (deficit) schizophrenia, and in 130 patients with a relapsing and remitting disease course. Specific DNA variants were associated with nondeficit schizophrenia, but not with the deficit syndrome. These findings suggest the existence of schizophrenia subtypes with distinct genetic causes. CART peptide levels are altered by a mutation associated with obesity at codon 34 G Dominguez, EM del Giudice, MJ Kuhar del Giudice et al (2001) reported a mutation in the CART gene that was associated with severe early-onset obesity in a large family. In this work, the authors showed for the first time that this mutation also has a cellular phenotype that affects the synthesis or processing of CART peptides. These results support the genetic data suggesting that this mutation may play a role in the obesity phenotype by altering CART peptide levels in the brain or in other tissues in humans.
ORIGINAL RESEARCH ARTICLES
A genome wide linkage study of obesity as a secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses YC Chagnon, C Me´rette, RH Bouchard, C E´mond, M-A Roy, M Maziade Antipsychotics that are used to control schizophrenia (SZ) and bipolar disorder (BP) symptoms could induce important weight gain and obesity. However, only a fraction of the patients showed such adverse effects. This susceptibility to develop side effects could be genetic in its origin. Using a genome scan among multigenerational SZ and BP families, the authors identified 12q24 including the pro-melanin concentrating hormone (PMCH) gene, as a susceptibility chromosomal region for antipsychotic-induced obesity. PMCH controls food intake and energy expenditure in rodents.
Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans J Licinio, F O'Kirwan, K Irizarry, B Merriman, S Thakur, R Jepson, S Lake, KG Tantisira, ST Weiss, M-L Wong
The authors reported an association of CRHR1 genotypes with the phenotype of antidepressant treatment response. Depressed patients were classified into high-anxiety or low-anxiety groups. The authors tested for haplotypic association between the CRHR1 gene and the response to antidepressant treatment using haplotype-tag single-nucleotide polymorphisms (htSNPs). In the high-anxiety group, homozygosity for the GAG haplotype was significantly associated with a relative greater reduction in anxiety and depression scores when compared to heterozygous.
A genome scan and follow-up study identify a bipolar disorder susceptibility locus on chromosome 1q42 S Macgregor, PM Visscher, SA Knott, P Thomson, DJ Porteous, JK Millar, RS Devon, D Blackwood, WJ Muir
The authors reported a genome scan for psychiatric disease susceptibility loci in 13 Scottish families. In this scan, they found linkage peaks on chromosomes 1, 3, 8, 9 and 19. The authors pursued the linkage peak on chromosome 1 in a larger sample of 22 families affected by schizophrenia (SCZ) or bipolar affective disorder (BPAD). In the larger sample, they obtained most evidence for linkage in BPAD families (but not SCZ families) near the previously identified SCZ susceptibility locus DISC1.
Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia N Park, SH Juo, R Cheng, J Liu, JE Loth, B Lilliston, J Nee, A Grunn, K Kanyas, B Lerer, J Endicott, TC Gilliam, M Baron Refined phenotypes could expedite gene detection. Bipolar disorder with psychosis may be one such phenotype. A genomewide screen supported linkage to psychotic BP on chromosomes 5q, 6q, 8p, 8q, 9q, 13q, 15q, 17p, 18q and 20q. For most locations, linkage was most pronounced in families with large concentration of psychosis. Some regions (9q, 15q, 17p, 20q) were novel, and several regions (5q, 6q, 8p, 13q, 15q, 17p, 18q) were also implicated in schizophrenia, suggesting shared susceptibility for the two disorders.
Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment IL Schurov, EJ Handford, NJ Brandon, PJ Whiting
The authors reported the protein expression profile of DISC1 in the adult and developing mouse brain. In the adult mouse brain DISC1 was expressed in neurons within various brain areas. During development, DISC1 protein was detected at all stages, from E10 to 6 months old, with two significant peaks of protein expression of a DISC1 isoform at E13.5 and P35. These time points corresponded to critical stages during mouse development, the active neurogenesis period in the developing brain and the period of puberty.
Support for EKN1 as the susceptibility locus for dyslexia on 15q21 KG Wigg, JM Couto, Y Feng, B Anderson, TD Cate-Carter, F Macciardi, R Tannock, MW Lovett, TW Humphries, CL Barr Dyslexia has been linked to a number of chromosomal regions including 15q. Recently, a gene, EKN1, in the linked region, was identified via a translocation breakpoint. In this sample of families, the authors found evidence for an association to dyslexia analyzed as a categorical trait, and to the reading and related processes of phonological awareness, word identification, decoding, rapid automatized naming, language ability, and verbal short-term memory. These findings provide support for EKN1 as a risk locus for dyslexia and as contributing to reading component processes and related abilities.
Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease B Funalot, T Ouimet, A Claperon, C Fallet, A Delacourte, J Epelbaum, T Subkowski, N Le´onard, V Codron, J-P David, P Amouyel, J-C Schwartz, N Helbecque Cerebral accumulation of b-amyloid peptide (Ab) is a central event in the pathogenesis of Alzheimer's disease (AD). The authors showed that endothelinconverting enzyme-1 (ECE-1), a candidate Ab-degrading enzyme, is expressed in various regions of human neocortex and hippocampus, further suggesting a physiological role in Ab clearance. They identified genetic polymorphisms in regulatory regions of the gene encoding ECE-1, and demonstrated association with AD risk in a case-control study involving 401 patients with late-onset AD and 461 aged controls.
Variations in estrogen receptor a gene, and risk of dementia, and brain volumes on MRI T den Heijer, SCE Schuit, HAP Pols, JBJ van Meurs, A Hofman, PJ Koudstaal, CM van Duijn, AG Uitterlinden, MMB Breteler
In a large population-based sample, the authors prospectively investigated the association between polymorphisms in the estrogen receptor (ER) a gene and risk of Alzheimer's disease. In part, they assessed volumes of the hippocampus and amygdala on MRI. There was no association between ERa polymorphisms and Alzheimer's disease, yet in women they found an association with amygdalar volumes on MRI. This finding may stimulate future research on estrogens in relation to psychiatric disorders in which the amygdala is involved.
